A Year in Review: Mark Cuban's Cost Plus Drugs and the PBM Industry

Roughly a year ago, we posted a blog as the fourth in a series following Mark Cuban and his newly founded company, Cost Plus Drugs Company (MCCPDC). You can find the previous four blogs at the following hyperlinks: Blog 1, Blog 2, Blog 3, and Blog 4. Now that a full year has passed, how is his progress going? More importantly, how are the competitors adjusting?

Over the past year, MCCPDC has made significant strides in its mission to disrupt the traditional pharmacy-benefit management (PBM) model. Ever since the announcement that Blue Shield of California is replacing CVS Caremark with a partnership that includes MCCPDC, Amazon Pharmacy, Abarca, and Prime Therapeutics, MCCPDC has expanded its scope and grown its influence in the healthcare market.

You may recall that two years ago, Cuban and his company built its first drug manufacturing facility. In March of this year, they began manufacturing their first generic drugs, starting off with epinephrine and norepinephrine. This move directly addresses one of the most pressing issues in American healthcare: drug shortages. By leveraging advanced robotic and AI technologies at their Dallas facility, MCCPDC aims to quickly respond to shortages, ensuring that critical medications remain accessible and affordable. This new capability not only enhances the company's ability to provide low-cost drugs but also solidifies its role in tackling inefficiencies in the drug supply chain. If their main goal of providing transparency and reducing costs fails, at the very least our country is now better equipped to prevent shortages of life-saving medication.

In April, Mark Cuban's Cost Plus Drug Company (MCCPDC) recently expanded its impact by partnering with Price.com to create a new platform to compare drug prices. This is an enhancement to their existing offerings, focusing specifically on price comparison across various providers. While MCCPDC’s current platform already provides transparent pricing for the medications they offer directly, this new initiative with Price.com broadens the scope by allowing consumers to compare drug prices from multiple sources, not just those provided by MCCPDC. At the press conference Price.com CEO RJ Jain said, “Teaming up with Mark Cuban Cost Plus Drug Company is a pivotal step towards achieving our shared goal of improving healthcare affordability and accessibility. Thanks to this collaboration, Price.com users can make informed choices that best suit their health and financial needs."

?

Competitors’ Reactions: Adjusting to a New Reality

The entrance of MCCPDC and the consortium of companies that Blue Shield of California has partnered with has forced traditional PBMs to rethink their strategies. CVS Health, which initially downplayed the impact of losing Blue Shield as a client, has since made several strategic adjustments to mitigate the effects. Walgreens has followed suit.

Faced with Cuban’s innovative website as its competitor, CVS Health has enhanced its digital platform, integrating AI to streamline prescription management and launched initiatives to offer competitive pricing and personalized healthcare services. Walgreens, on the other hand, has expanded its telehealth services and invested in strengthening its supply chain to better manage drug shortages. These strategic shifts are designed to improve accessibility, affordability, and convenience for consumers, as both companies seek to maintain their market share in the face of MCCPDC's growing influence.

?

Regulatory and Legislative Pressures

Fortunately, regulatory scrutiny on traditional PBMs has intensified. In July 2024, the Federal Trade Commission (FTC) released a report criticizing the practices of major PBMs, including CVS Caremark and Express Scripts, for contributing to rising prescription drug costs and limiting consumer access to medications. The report highlighted how these PBMs often operate with a lack of transparency, influencing drug prices and availability without sufficient accountability. The FTC's ongoing investigation is part of a broader effort to regulate the industry more closely, which could significantly impact the business models of these traditional PBMs as they struggle to adapt to new competitors that are embracing price transparency. In a statement, FTC Chair Lina Khan said, “The FTC will continue to use all our tools and authorities to scrutinize dominant players across healthcare markets and ensure that Americans can access affordable healthcare.”

?

Looking Ahead: The Future of PBMs

As we look forward, it’s clear that the traditional PBM industry is under significant pressure from both market disruptors and regulatory bodies. The success of MCCPDC and similar ventures has demonstrated that there is a viable alternative to the opaque pricing models that have dominated the industry for so long. As more insurers and consumers become aware of these alternatives, the pressure on traditional PBMs to adapt—or risk losing market share—will only grow.

What we’ve continued to see is that MCCPDC’s model of transparency and consumer-first pricing is a challenge to the status quo. However, now it’s becoming clear that it is a sustainable business approach that could reshape the healthcare landscape. The coming years will be critical as we see whether these changes lead to a more equitable and affordable healthcare system for all. Stay tuned as we continue to track this evolving story and its implications for the future of healthcare.

www.dwmgmt.com